JNJ and LEGN Biotech Face FDA Scrutiny Over Carvykti Supplemental License Application
Washington, D.C. — The FDA’s Oncologic Drugs Advisory Committee is set to convene on Friday to deliberate on Johnson & Johnson and Legend Biotech Corporation’s supplemental biologics license application for Carvykti. This drug is intended for patients with relapsed or refractory multiple myeloma who have undergone previous lines of therapy. The panel will specifically analyze … Read more